In a series of 53 patients with advanced anal squamous cell cancer, we demonstrate that a modified 5-fluorouracil and cisplatin schedule (FOLFCIS) with lower dose, more frequent administration of cisplatin is effective and well-tolerated. This regimen should be considered a standard treatment option. Human papillomavirus-negative anal squamous cell cancers were less sensitive to platinum-based therapy and exhibited a distinct molecular profile. Background: Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC. Patients and Methods: We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy e essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin e in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers. Results: Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirusnegative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations. Conclusions: FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients.
Introduction
In 2017 in the United States, there were an estimated 8200 new cases of anal squamous cell cancer (SCC), and 1100 patients died from this disease. 1 The incidence of anal SCC is rising, particularly in high-risk groups, such as transplant recipients, men who have sex with men, and those with HIV. 2 Human papillomavirus (HPV) has been recognized as a key driver of the carcinogenesis of anal SCC, and its DNA is found in 88% of tumors. 3, 4 Most patients are diagnosed with early-stage tumors in the anal canal, and over the past 40 years, the standard treatment for localized anal SCC has been chemoradiotherapy with a fluoropyrimidine (5-fluorouracil or, more recently, capecitabine) and mitomycin C. 5, 6 In patients with persistent disease or local recurrence, salvage abdominoperineal resection is the treatment of choice. 7 Given the high success of chemoradiotherapy in early-stage disease and the relatively low incidence of anal cancer, there is limited evidence for systemic regimens in the metastatic setting. 8 National Comprehensive Care
Network guidelines recommend that treatment for patients with distant metastasis be individualized and note that metastatic disease is usually treated with cisplatin-based chemotherapy or the combination of carboplatin plus paclitaxel. 9 More recently the programmed death-1 inhibitors nivolumab and pembrolizumab have also shown activity. 10, 11 The combination of cisplatin and 5-FU (CF), typically with high-dose cisplatin on day 1 and 5-FU given as a 4-day infusion, each once every 4 weeks, is the most commonly used first-line metastatic regimen, but the evidence supporting its efficacy and safety comes from small institutional series. 12, 13 Responses to this regimen are heterogeneous, ranging from complete clinical responses to primarily resistant disease; no biomarker predictive of treatment sensitivity is currently available. Furthermore, cisplatinbased regimens are associated with high toxicity, including nausea, acute kidney injury, and hearing impairment, which can be associated with a negative impact on quality of life. 14 Taxane-based regimens have also been studied in small cohorts with variable success. 15, 16 Given these concerns, at Memorial Sloan Kettering
Cancer Center (MSKCC), the original CF protocol was modified, based on the success and tolerability of the FOLFOX (leucovorin, fluorouracil, and oxaliplatin) regimen, to approximate FOLFOX with cisplatin substituted for oxaliplatin. In this regimen, cisplatin is administrated at a lower dose every 2 weeks (FOLFCIS) instead of every 3 or 4 weeks. We now report the outcomes of patients with metastatic anal cancer treated with FOLFCIS in a large institutional series. In addition, using a multi-gene hybridization capture nextgeneration sequencing assay, we analyzed a subgroup of anal SCC specimens to evaluate for genomic markers of response and identify key genomic drivers.
Patients and Methods

Patients
We performed a search of the electronic medical records of MSKCC to identify all patients seen between January 1, 2000 and June 30, 2017 with a diagnosis of tumor of the anal canal and reviewed pharmacology records for treatment with cisplatin, carboplatin, or paclitaxel. We noted that the FOLFCIS regimen started to be commonly used in treatment in 2007, and therefore cases identified in this query were manually reviewed to select patients with advanced anal SCC who received treatment between January 1, 2007 and June 30, 2017 ( Figure 1 ). We verified pathologic diagnosis of anal SCC in all cases. Patients had either advanced disease at diagnosis or recurrence after definitive radiation or surgery. Patients were required to have either received systemic treatment at MSKCC or have had oncology consultation and subsequent regular evaluations at MSKCC.
Data Collection
Extracted clinical data included gender, age at diagnosis, comorbidities, tumor stage, tumor histology, treatment history, toxicity, and clinical outcomes. Staging was based on the seventh edition of American Joint Commission on Cancer staging criteria. This study was conducted under appropriate Institutional Review Board/Privacy Board protocols and waivers (IRB #17-530) and conducted in accordance with recognized ethical guidelines.
HPV Testing
HPV status was assessed by immunohistochemistry for p16 overexpression, HPV chromogenic in situ hybridization with highrisk HPV probes, or high-risk HPV RNA test on formalin-fixed paraffin-embedded tissue. Immunohistochemical analysis for p16 
Statistical Analysis
Descriptive statistics were used to summarize patient characteristics and response. Response was assessed by an expert radiologist (D.B.) based on clinical imaging performed while on first-line chemotherapy in all patients with anal cancer and classified required. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Both OS and PFS were calculated from first-line treatment start date. In case the treating clinician determined progressive disease (PD) based on imaging, but re-review of the imaging was not consistent with PD, it was still considered as an event. Patients without complete survival data were censored at date of last follow-up. Statistical software (SAS version 9.3) was used for statistical analyses.
Molecular Profiling
Since 2014, MSK-IMPACT, a custom next-generation hybridization capture sequencing platform, has been used at MSKCC to genotype metastatic tumors to identify patients for clinical trials. 
Genomic Analysis
Significantly recurrently mutated genes were identified using MutSigCV algorithm 19, 20 and hotspot enrichment and truncating enrichment analyses. 21 Genes with q-values < 0.1 were considered to be significantly recurrently mutated. Oncogenic or likely oncogenic genetic variants were identified using OncoKB, 22 a precision oncology database that tracks the effects of cancer variants and their potential clinical actionability. Log-rank test was used to evaluate for associations between genomic alterations and survival, and the 2-sided Fisher exact test was used to evaluate for correlations between genomic changes and response to treatment.
Results
Patients and Treatment
Patient Characteristics. We identified 87 patients with metastatic or locally recurrent, unresectable anal cancer who received first-line systemic chemotherapy at MSKCC during this period ( Figure 1 ). Fifty-three of these patients received the FOLFCIS regimen. Baseline characteristics of the FOLFCIS group and patients treated with other regimens are summarized in Table 1 . Baseline characteristics were similar between the 2 groups. In the FOLFCIS group, most patients presented with local-regional disease, most commonly stage III (34%). Among patients with initially local-regional disease, the median time from diagnosis to the development of metastatic diseases was 16.5 months. Eight (15%) patients had some form of immunosuppression, including HIV infection, anti-TNF therapy, or immunosuppressive medications after solid organ transplant. HPV status was available for 34 (64%) patients and was positive in Treatment. The median number of cycles of FOLFCIS was 7 (range, 1-53 cycles). The median dose intensities for cisplatin, bolus 5-FU, and infusion 5-FU were 84%, 85%, and 96%, respectively. Second-line systemic treatment was administered in 28 (53%) patients and a third-line treatment in 11 (19%) patients. Thirteen (25%) patients received multimodality treatment for metastatic disease, with surgery the most frequent additional modality (Table 2 ).
Safety and Activity of FOLFCIS
Toxicity. Attributable adverse events to FOLFCIS are listed in Table 3 . The most prevalent grade 3 to 4 toxicities included neutropenia (34%), anemia (19%), fatigue (9%), and dehydration (8%). There was 1 (2%) patient with grade 3 febrile neutropenia. There was no grade 5 toxicity. In the subgroup of patients with immunosuppression (n ¼ 8), we noted a higher incidence of grade 3 to 4 diarrhea, which occurred in 25% of patients with a history of immunosuppression compared to 2% of non-immunosuppressed patients (P ¼ .01). There was no difference in other grade 3 to 4 toxicities.
Outcomes. Forty-six patients had RECIST measurable disease for evaluation of treatment response to FOLFCIS. The response rate was 48% (95% confidence interval [CI], 32.6%-63%), with 9% of patients achieving a complete response. An additional 20% (95% CI, 8.7%-32.6%) had stable disease (Table 4) . In 15% of patients, there was no further imaging evaluation because of clinical deterioration. With a median follow-up of 41.6 months, PFS and OS were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively (Figure 2) . Among the 4 patients with complete response to FOLFCIS, all had liver metastases, with 1 patient also having lung metastasis and another also with distant nodal metastasis, and all remain alive, with 3 patients still disease-free. In the subgroup that was treated with other regimens, the response rate, median PFS, and OS were 23% (95% CI, 7.8%-45.4%), 6.4 months (95% CI, 4.3-7.5 months), and 17.2 months (95% CI, 13.2-21.2 months), respectively.
Translational Analysis
To evaluate for genomic markers of response to platinum-based therapy and to identify key genomic drivers of anal cancer, 45 advanced anal SCC specimens underwent prospective, targeted next-generation sequencing analysis of paired tumor and normal samples (Figure 3) . The average depth of coverage across all tumor samples was 713X. Filtering for known oncogenic alterations using OncoKB, a mean of 3.26 oncogenic genomic alterations per sample were identified. The most frequent genomic alterations consisted of chromosome 3q amplification (51%) with focal 3q amplifications (primarily affecting PIK3CA or TP63 in the targeted assay) in onethird of cases, and of mutations in PIK3CA (29%) and KMT2D (22%). Genomic alterations affecting the phosphatidylinositol 3-kinase (PI3K) pathway in PIK3CA, PTEN, or AKT2 were detected in 44% of cases. MSK-IMPACT testing changed the clinical management of 4 (13%) patients: 3 patients with tumor PIK3CA mutations enrolled in trials of PI3K inhibitors and 1 patient with tumor ERBB2 mutation enrolled in a trial of a pan-HER kinase inhibitor.
We evaluated for associations between genomic alterations and best response to platinum-containing treatment in 31 patients with advanced anal SCC and MSK-IMPACT tumor testing (see Supplemental Table 2 in the online version). Across the cohort, no genomic alteration associated with response to FOLFCIS (Figure 3 , left panel). Tumor mutation burden also did not correlate with response to platinum-containing therapy. In the 3 patients with HPV-negative anal SCC, 2 had measurable disease, and both had increased disease at first imaging after FOLFCIS e measured as RECIST stable disease (SD) in 1 case (16% increase in sum of diameters) and progressive disease (PD) in the other; the third had locally recurrent disease with clinical progression on FOLFCIS. The 3 HPV-negative cases all had TP53, TERT promoter, and CDKN2A 
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mutations, and 2 of these 3 cases harbored YAP1 amplification. No TERT promoter alterations were identified in HPV-positive anal cancer, and TP53 mutations were infrequent in HPV-positive cases. We evaluated for associations between recurrent genomic alterations affecting at least 3 cases in the cohort and OS (see Supplemental Figure 1 in the online version). CDKN2A, TP53, YAP1, and TERT alterations e all genomic alterations enriched in HPVnegative cases e were each significantly associated with OS.
Discussion
Here we report treatment of 53 patients with a novel schedule of cisplatin and 5-fluorouracil every 2 weeks (FOLFCIS) where we observed a RECIST response rate of 48%. This regimen achieved a PFS of 7.1 months and OS of 22.1 months and was well-tolerated. Our outcomes compare well with the activity of other regimens in modern series. 23, 24 For instance, a recent series from MD Anderson of metastatic or unresectable locally recurrent anal SCC treated with systemic treatment reported PFS of 7 months and OS of 22 months. In that cohort, the most frequently used regimens were cisplatin/fluorouracil (55%) and paclitaxel/carboplatin (31%). 23 There are no biomarkers currently available for treatment sensitivity, and we performed an integrated clinical and genomic analysis. We identified recurrent, potentially targetable alterations in the PI3K pathway involving many advanced anal SCC (44%), consistent with previous series of advanced anal cancer. 25, 26 No genomic alteration or tumor mutation burden correlated with response to platinum-containing treatment, suggesting that factors besides genetic changes may modulate response to platinum therapy in anal cancer. The high frequency of alterations involving the histone methyltransferases KMT2D and KMT2C suggest that aberrant epigenetic regulation may play an important role in anal SCC, and it is possible that expression profiling may better identify a marker for platinum sensitivity. Although there were few cases, patients in our series with HPV-negative anal cancer had distinct genomics compared with HPV-positive cases. HPV-negative anal cancer has been associated with loss-of-function mutations in TP53 and CDKN2A. 25 TP53 mutations have also been associated with increased recurrence risk. 27 Our study is limited as a retrospective analysis, and thus the estimation of PFS may not be entirely accurate. However, we were able to assess treatment administration, response, toxicity, and outcomes in a large series of patients with advanced anal cancer in a real-world clinical setting. Based on the study design, we cannot directly compare the tolerability and efficacy of FOLFCIS to standard high-dose cisplatin regimens. However, our outcomes with FOLFCIS are comparable to those with high-dose cisplatin, and patients tolerated FOLFCIS well with no need for high-dose cisplatin pre-hydration and were able to achieve a high-dose intensity of both cisplatin and 5-FU with this schedule. Furthermore, the frequency of grade 3/4 toxicity was consistent with a better safety profile for more frequent lower dose cisplatin, as has been demonstrated in other solid tumors. 28, 29 Recently a modified regimen of docetaxel, cisplatin, and 5-FU (DCF) every 2 weeks has shown an encouraging 83% response rate in this population and better tolerability compared with standard DCF. 30 The ongoing
International Advanced Anal Cancer Trial, a randomized phase II study that is comparing efficacy and safety of carboplatin plus paclitaxel versus cisplatin and 5-FU for the first-line treatment in this setting (NCT02051868), will further guide whether a taxanecontaining regimen is more effective or better tolerated than a cisplatin-based regimen. Our data support the clinically relevant benefit of chemotherapy in these patients and suggest that FOLF-CIS should be considered a standard clinical option for patients with advanced anal cancer.
Clinical Practice Points
The combination of high-dose cisplatin and 5-fluorouracil is standard treatment for advanced anal SCC and is associated with significant toxicity and variable efficacy.
In this retrospective cohort, 53 patients with advanced anal SCC received first-line FOLFCIS, a FOLFOX schedule with cisplatin substituted for oxaliplatin, with a response rate of 48% and progression-free survival of 7.1 months. The median dose intensities for cisplatin, bolus 5-FU, and infusion 5-FU were 84%, 85%, and 96%, respectively. This regimen was well-tolerated, and only 1 (2%) patient developed febrile neutropenia. There was no grade 5 toxicity. A subgroup of patients underwent deep sequencing, and no genomic alteration correlated with response to platinumcontaining treatment. HPV-negative cases were enriched of CDKN2A, TP53, YAP1, and TERT alterations, which were associated with worse OS. FOLFCIS is effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. These results further suggest that more frequent lower dose of cisplatin is better tolerated in patients with advanced malignancies.
Supplemental Table 1 Gene Lists for MSK-IMPACT Platform Versions 1 (341 Genes), 2 (410 Genes), and 3 (468 Genes)   IMPACT 341  IMPACT 410  IMPACT 468   ABL1  ABL1  ABL1  AKT1  ACVR1  ACVR1  AKT2  AKT1  AGO2  AKT3  AKT2  AKT1  ALK  AKT3  AKT2  ALOX12B  ALK  AKT3  AMER1  ALOX12B  ALK  APC  AMER1  ALOX12B  AR  ANKRD11  AMER1  ARAF  APC  ANKRD11  ARID1A  AR  APC  ARID1B  ARAF  AR  ARID2  ARID1A  ARAF  ARID5B  ARID1B  ARID1A  ASXL1  ARID2  ARID1B  ASXL2  ARID5B  ARID2  ATM  ASXL1  ARID5B  ATR  ASXL2  ASXL1  ATRX  ATM  ASXL2  AURKA  ATR  ATM  AURKB  ATRX  ATR  AXIN1  AURKA  ATRX  AXIN2  AURKB  AURKA  AXL  AXIN1  AURKB  B2M  AXIN2  AXIN1  BAP1  AXL  AXIN2  BARD1  B2M  AXL  BBC3  BAP1  B2M  BCL2  BARD1  BABAM1  BCL2L1  BBC3  BAP1  BCL2L11  BCL10  BARD1  BCL6  BCL2  BBC3  BCOR  BCL2L1  BCL10  BLM  BCL2L11  BCL2  BMPR1A  BCL6  BCL2L1  BRAF  BCOR  BCL2L11  BRCA1  BIRC3  BCL6  BRCA2  BLM  BCOR  BRD4  BMPR1A  BIRC3  BRIP1  BRAF  BLM  BTK  BRCA1  BMPR1A  CARD11  BRCA2  BRAF  CASP8  BRD4  BRCA1  CBFB  BRIP1  BRCA2  CBL  BTK  BRD4  CCND1  CALR  BRIP1  CCND2  CARD11  BTK  CCND3  CASP8  CALR  CCNE1  CBFB  CARD11  CD274  CBL  CARM1  CD276 CCND1 CASP8
Supplemental Table 1 Continued   IMPACT 341  IMPACT 410  IMPACT 468   CD79B  CCND2  CBFB  CDC73  CCND3  CBL  CDH1  CCNE1  CCND1  CDK12  CD274  CCND2  CDK4  CD276  CCND3  CDK6  CD79A  CCNE1  CDK8  CD79B  CD274  CDKN1A  CDC73  CD276  CDKN1B  CDH1  CD79A  CDKN2A  CDK12  CD79B  CDKN2B  CDK4  CDC42  CDKN2C  CDK6  CDC73  CHEK1  CDK8  CDH1  CHEK2  CDKN1A  CDK12  CIC  CDKN1B  CDK4  CREBBP  CDKN2A  CDK6  CRKL  CDKN2B  CDK8  CRLF2  CDKN2C  CDKN1A  CSF1R  CEBPA  CDKN1B  CTCF  CENPA  CDKN2A  CTLA4  CHEK1  CDKN2B  CTNNB1  CHEK2  CDKN2C  CUL3  CIC  CEBPA  DAXX  CREBBP  CENPA  DCUN1D1  CRKL  CHEK1  DDR2  CRLF2  CHEK2  DICER1  CSF1R  CIC  DIS3  CSF3R  CREBBP  DNMT1  CTCF  CRKL  DNMT3A  CTLA4  CRLF2  DNMT3B  CTNNB1  CSDE1  DOT1L  CUL3  CSF1R  E2F3  CXCR4  CSF3R  EED  DAXX  CTCF  EGFL7  DCUN1D1  CTLA4  EGFR  DDR2  CTNNB1  EIF1AX  DICER1  CUL3  EP300  DIS3  CXCR4  EPCAM  DNAJB1  CYLD  EPHA3  DNMT1  CYSLTR2  EPHA5  DNMT3A  DAXX  EPHB1  DNMT3B  DCUN1D1  ERBB2  DOT1L  DDR2  ERBB3  E2F3  DICER1  ERBB4  EED  DIS3  ERCC2  EGFL7  DNAJB1  ERCC3  EGFR  DNMT1  ERCC4  EIF1AX  DNMT3A  ERCC5  EIF4A2  DNMT3B  ERG  EIF4E  DOT1L  ESR1  EP300  DROSHA  ETV1 EPCAM DUSP4
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Supplemental Table 1 Continued   IMPACT 341  IMPACT 410  IMPACT 468   ETV6  EPHA3  E2F3  EZH2  EPHA5  EED  FAM175A  EPHA7  EGFL7  FAM46C  EPHB1  EGFR  FANCA  ERBB2  EIF1AX  FANCC  ERBB3  EIF4A2  FAT1  ERBB4  EIF4E  FBXW7  ERCC2  ELF3  FGF19  ERCC3  EP300  FGF3  ERCC4  EPAS1  FGF4  ERCC5  EPCAM  FGFR1  ERG  EPHA3  FGFR2  ERRFI1  EPHA5  FGFR3  ESR1  EPHA7  FGFR4  ETV1  EPHB1  FH  ETV6  ERBB2  FLCN  EZH2  ERBB3  FLT1  FAM175A  ERBB4  FLT3  FAM46C  ERCC2  FLT4  FANCA  ERCC3  FOXA1  FANCC  ERCC4  FOXL2  FAT1  ERCC5  FOXP1  FBXW7  ERF  FUBP1  FGF19  ERG  GATA1  FGF3  ERRFI1  GATA2  FGF4  ESR1  GATA3  FGFR1  ETV1  GNA11  FGFR2  ETV6  GNAQ  FGFR3  EZH1  GNAS  FGFR4  EZH2  GREM1  FH  FAM175A  GRIN2A  FLCN  FAM46C  GSK3B  FLT1  FAM58A  H3F3C  FLT3  FANCA  HGF  FLT4  FANCC  HIST1H1C  FOXA1  FAT1  HIST1H2BD  FOXL2  FBXW7  HIST1H3B  FOXO1  FGF19  HNF1A  FOXP1  FGF3  HRAS  FUBP1  FGF4  ICOSLG  FYN  FGFR1  IDH1  GATA1  FGFR2  IDH2  GATA2  FGFR3  IFNGR1  GATA3  FGFR4  IGF1  GLI1  FH  IGF1R  GNA11  FLCN  IGF2  GNAQ  FLT1  IKBKE  GNAS  FLT3  IKZF1  GPS2  FLT4  IL10  GREM1  FOXA1  IL7R  GRIN2A  FOXL2  INPP4A  GSK3B  FOXO1 PARK2  MCL1  KMT2B  PARP1  MDC1  KMT2C  PAX5  MDM2  KMT2D  PBRM1  MDM4  KMT5A  PDCD1  MED12  KNSTRN  PDGFRA  MEF2B  KRAS  PDGFRB  MEN1  LATS1  PDPK1  MET  LATS2  PHOX2B  MGA  LMO1  PIK3C2G  MITF  LYN  PIK3C3  MLH1  MALT1  PIK3CA  MPL  MAP2K1  PIK3CB  MRE11  MAP2K2  PIK3CD  MSH2  MAP2K4  PIK3CG  MSH6  MAP3K1  PIK3R1  MST1  MAP3K13  PIK3R2  MST1R  MAP3K14  PIK3R3  MTOR  MAPK1  PIM1  MUTYH  MAPK3  PLK2  MYC  MAPKAP1  PMAIP1  MYCL  MAX  PMS1  MYCN  MCL1  PMS2  MYD88  MDC1  PNRC1  MYOD1  MDM2  POLE  NBN  MDM4  PPP2R1A  NCOA3  MED12  PRDM1  NCOR1  MEF2B  PRKAR1A  NEGR1  MEN1  PTCH1  NF1  MET  PTEN  NF2  MGA  PTPN11  NFE2L2  MITF  PTPRD  NFKBIA  MLH1  PTPRS NKX2-1 MPL Supplemental Table 1 Continued   IMPACT 341  IMPACT 410  IMPACT 468   PTPRT  NKX3-1  MRE11  RAC1  NOTCH1  MSH2  RAD50  NOTCH2  MSH3  RAD51  NOTCH3  MSH6  RAD51B  NOTCH4  MSI1  RAD51C  NPM1  MSI2  RAD51D  NRAS  MST1  RAD52  NSD1  MST1R  RAD54L  NTRK1  MTOR  RAF1  NTRK2  MUTYH  RARA  NTRK3  MYC  RASA1  NUP93  MYCL  RB1  PAK1  MYCN  RBM10  PAK5  MYD88  RECQL4  PALB2  MYOD1  REL  PARK2  NBN  RET  PARP1  NCOA3  RFWD2  PAX5  NCOR1  RHOA  PBRM1  NEGR1  RICTOR  PDCD1  NF1  RIT1  PDGFRA  NF2  RNF43  PDGFRB  NFE2L2  ROS1  PDPK1  NFKBIA  RPS6KA4  PGR  NKX2-1  RPS6KB2  PHOX2B  NKX3-1  RPTOR  PIK3C2G  NOTCH1  RUNX1  PIK3C3  NOTCH2  RYBP  PIK3CA  NOTCH3  SDHA  PIK3CB  NOTCH4  SDHAF2  PIK3CD  NPM1  SDHB  PIK3CG  NRAS  SDHC  PIK3R1  NSD1  SDHD  PIK3R2  NTHL1  SETD2  PIK3R3  NTRK1  SF3B1  PIM1  NTRK2  SH2D1A  PLCG2  NTRK3  SHQ1  PLK2  NUF2  SMAD2  PMAIP1  NUP93  SMAD3  PMS1  PAK1  SMAD4  PMS2  PAK5  SMARCA4  PNRC1  PALB2  SMARCB1  POLD1  PARK2  SMARCD1  POLE  PARP1  SMO  PPM1D  PAX5  SOCS1  PPP2R1A  PBRM1  SOX17  PPP6C  PDCD1  SOX2  PRDM1  PDCD1LG2  SOX9  PRKAR1A  PDGFRA  SPEN  PTCH1  PDGFRB  SPOP  PTEN  PDPK1  SRC  PTPN11  PGR  STAG2 PTPRD PHOX2B
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Supplemental Table 1 Continued   IMPACT 341  IMPACT 410  IMPACT 468   STK11  PTPRS  PIK3C2G  STK40  PTPRT  PIK3C3  SUFU  RAB35  PIK3CA  SUZ12  RAC1  PIK3CB  SYK  RAD21  PIK3CD  TBX3  RAD50  PIK3CG  TERT  RAD51  PIK3R1  TET1  RAD51B  PIK3R2  TET2  RAD51C  PIK3R3  TGFBR1  RAD51D  PIM1  TGFBR2  RAD52  PLCG2  TMEM127  RAD54L  PLK2  TMPRSS2  RAF1  PMAIP1  TNFAIP3  RARA  PMS1  TNFRSF14  RASA1  PMS2  TOP1  RB1  PNRC1  TP53  RBM10  POLD1  TP63  RECQL4  POLE  TRAF7  REL  PPARG  TSC1  RET  PPM1D  TSC2  RFWD2  PPP2R1A  TSHR  RHEB  PPP4R2  U2AF1  RHOA  PPP6C  VHL  RICTOR  PRDM1  VTCN1  RIT1  PRDM14  WT1  RNF43  PREX2  XIAP  ROS1  PRKAR1A  XPO1  RPS6KA4  PRKCI  YAP1  RPS6KB2  PRKD1  YES1  RPTOR  PTCH1  RUNX1  PTEN  RYBP  PTP4A1  SDHA  PTPN11  SDHAF2  PTPRD  SDHB  PTPRS  SDHC  PTPRT  SDHD  RAB35  SETD2  RAC1  SF3B1  RAC2  SH2B3  RAD21  SH2D1A  RAD50  SHQ1  RAD51  SMAD2  RAD51B  SMAD3  RAD51C  SMAD4  RAD51D  SMARCA4  RAD52  SMARCB1  RAD54L  SMARCD1  RAF1  SMO  RARA  SOCS1  RASA1  SOX17  RB1  SOX2  RBM10  SOX9 RECQL Supplemental Table 1 Continued   IMPACT 341  IMPACT 410  IMPACT 468   SPEN  RECQL4  SPOP  REL  SRC  RET  SRSF2  RFWD2  STAG2  RHEB  STAT3  RHOA  STAT5A  RICTOR  STAT5B  RIT1  STK11  RNF43  STK40  ROS1  SUFU  RPS6KA4  SUZ12  RPS6KB2  SYK  RPTOR  TBX3  RRAGC  TCEB1  RRAS  TCF3  RRAS2  TCF7L2  RTEL1  TERT  RUNX1  TET1  RXRA  TET2  RYBP  TGFBR1  SDHA  TGFBR2  SDHAF2  TMEM127  SDHB  TMPRSS2  SDHC  TNFAIP3  SDHD  TNFRSF14  SESN1  TOP1  SESN2  TP53  SESN3  TP63  SETD2  TRAF2  SF3B1  TRAF7  SH2B3  TSC1  SH2D1A  TSC2  SHOC2  TSHR  SHQ1  U2AF1  SLX4  VEGFA  SMAD2  VHL  SMAD3  VTCN1  SMAD4  WT1  SMARCA4  XIAP  SMARCB1  XPO1  SMARCD1  XRCC2  SMO  YAP1  SMYD3  YES1  SOCS1  ZFHX3  SOS1  ZRSR2  SOX17  SOX2  SOX9  SPEN  SPOP  SPRED1 SRC SRSF2
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Supplemental Table 1 Continued   IMPACT 341  IMPACT 410  IMPACT 468   STAG2  STAT3  STAT5A  STAT5B  STK11  STK19  STK40  SUFU  SUZ12  SYK  TAP1  TAP2  TBX3  TCEB1  TCF3  TCF7L2  TEK  TERT  TET1  TET2  TGFBR1  TGFBR2  TMEM127  TMPRSS2  TNFAIP3  TNFRSF14  TOP1  TP53  TP53BP1  TP63  TRAF2  TRAF7  TSC1  TSC2  TSHR  U2AF1  UPF1  VEGFA  VHL  VTCN1  WHSC1  WHSC1L1  WT1  WWTR1  XIAP  XPO1  XRCC2  YAP1  YES1  ZFHX3  ZRSR2 Abbreviation: MSK-IMPACT ¼ Memorial Sloan Kettering Integrated Molecular Profiling of Actionable Cancer Targets.
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